PetCaseFinder

Peer-reviewed veterinary case report

Gene and protein markers in canine oral melanoma tumors

By Nordio, Laura et al.·Published in Frontiers in veterinary science·2021·Department of Veterinary Medicine (DIMEVET), Italy·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Molecular and Immunohistochemical Expression of LTA4H and FXR1 in Canine Oral Melanoma.

Species:
dog

Plain-English summary

A study looked at oral melanoma, a common and serious type of tumor in dogs, to understand the presence of certain proteins (LTA4H and FXR1) that might relate to how aggressive the cancer is. Researchers examined 36 tumors and found that while these proteins were present in nearly all cases, their levels did not seem to connect with traditional measures of tumor growth or behavior. This suggests that while LTA4H and FXR1 are common in these tumors, they might not help predict how the cancer will act. More research is needed to understand their role in this type of cancer.

People also search for: dog oral melanoma treatment · canine melanoma prognosis · LTA4H FXR1 in dog tumors

Abstract

Oral melanoma is a common canine tumor whose prognosis is considered ominous, but poorly predicted by histology alone. In the present study the gene and protein expression of Leukotriene A4 hydrolase (LTA4H) and Fragile-X-mental retardation-related protein1 (FXR1), both reported as related to metastatic potential in different tumors, were investigated in canine oral melanoma. The main aim of the study was to confirm and quantify the presence of LTA4H and FXR1 genes and protein in oral melanomas. A secondary aim was to investigate their association with histologic prognostic criteria (mitotic count, Ki-67 index). Formalin-fixed-paraffin-embedded canine oral melanomas (36) were collected and histopathological evaluation carried out. Immunolabelling for LTA4H and FXR1 and Ki-67 were performed. RT-PCR evaluated LTA4H and FXR1 gene expressions. Histologically, most tumors were epithelioid cell melanomas (19/36) and were amelanotic, mildly or moderately pigmented (5, 12 and 13/36 respectively), only 6 were highly pigmented. Mitotic count ranged 1-106, Ki-67 index ranged 4.5-52.3. Thirty-two (32/32) melanomas immunolabelled for LTA4H and 33/34 for FXR1. RT-PCR values ranged 0.76-5.11 ΔCt for LTA4H and 0.22-6.24 ΔCt for FXR1. Molecular and immunohistochemical expression of both LTA4H and FXR1 did not statically correlate with mitotic count or Ki-67 index. The present study demonstrates LTA4H and FXR1 gene and protein in canine oral melanoma, however their expression is apparently unrelated to histopathologic prognostic criteria. Although LTA4H and FXR1 seem unrelated to tumor behavior, their extensive expression in the present cohort of cases suggest that they may play a role in canine oral melanoma oncogenesis.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34966807/